Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss

Liver Transplantation

Volumn 20, Issue 2, 2014, Pages 218-227

  O'Leary, Jacqueline G ^a   Kaneku, Hugo ^b,c   Demetris, Anthony J ^d   Marr, John D ^a   Shiller, S Michelle ^a   Susskind, Brian M ^a   Tillery, Glenn W ^a   Terasaki, Paul I ^b,c   Klintmalm, Göran B ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TERASAKI FOUNDATION LABORATORY   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ALLOGRAFTS; ANTIBODIES; BIOPSY; COMPLEMENT C4B; FEMALE; GRAFT REJECTION; HLA ANTIGENS; HUMANS; ISOANTIBODIES; LIVER; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MICROCIRCULATION; MIDDLE AGED; PEPTIDE FRAGMENTS; REOPERATION; RETROSPECTIVE STUDIES; TIME FACTORS; VASCULITIS; YOUNG ADULT;

EID: 84894980938     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23788     Document Type: Article

References (39)

1. Starzl TE, Demetris AJ, Todo S, Kang Y, Tzakis A, Duquesnoy R, et al. Evidence for hyperacute rejection of human liver grafts: the case of the canary kidneys. Clin Transplant 1989; 3: 37-45.
2. Takaya S, Duquesnoy R, Iwaki Y, Demetris J, Yagihashi A, Bronsther O, et al. Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. Transplant Proc 1991; 23 (pt 1): 396-399.
3. Ogura K, Koyama H, Takemoto S, Terasaki PI, Busuttil RW,. Significance of a positive crossmatch on outcome in human liver transplantation. Transplant Proc 1992; 24: 1465.
4. Mañez R, Kelly RH, Kobayashi M, Takaya S, Bronsther O, Kramer D, et al. Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: studies toward further defining their significance. Hepatology 1995; 21: 1345-1352.
5. Demetris AJ, Nakamura K, Yagihashi A, Iwaki Y, Takaya S, Hartman GG, et al. A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology 1992; 16: 671-681.
6. Nakamura K, Yagihashi A, Iwaki Y, Takaya S, Hartman GG, Murase N, et al. The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis. Transplant Proc 1991; 23: 3021-3022.
7. Castillo-Rama M, Castro MJ, Bernardo I, Meneu-Diaz JC, Elola-Olaso AM, Calleja-Antolin SM, et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: role of human leukocyte antigen compatibility. Liver Transpl 2008; 14: 554-562.
8. Kozlowski T, Rubinas T, Nickeleit V, Woosley J, Schmitz J, Collins D, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl 2011; 17: 357-368.
9. Kozlowski T, Andreoni K, Schmitz J, Hayashi PH, Nickeleit V,. Sinusoidal C4d deposits in liver allografts indicate an antibody-mediated response: diagnostic considerations in the evaluation of liver allografts. Liver Transpl 2012; 18: 641-658.
10. Lunz J, Ruppert KM, Cajaiba MM, Isse K, Bentlejewski CA, Minervini M, et al. Re-examination of the lymphocytotoxic crossmatch in liver transplantation: can C4d stains help in monitoring? Am J Transplant 2012; 12: 171-182.
11. Sakashita H, Haga H, Ashihara E, Wen MC, Tsuji H, Miyagawa-Hayashino A, et al. Significance of C4d staining in ABO-identical/compatible liver transplantation. Mod Pathol 2007; 20: 676-684.
12. Musat AI, Agni RM, Wai PY, Pirsch JD, Lorentzen DF, Powell A, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011; 11: 500-510.
13. O'Leary JG, Kaneku H, Jennings LW, Bañuelos N, Susskind BM, Terasaki PI, Klintmalm GB,. Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transpl 2013; 19: 973-980.
14. Mañez R, Kobayashi M, Takaya S, Bronsther O, Kramer D, Bonet H, et al. Humoral rejection associated with antidonor lymphocytotoxic antibodies following liver transplantation. Transplant Proc 1993; 25 (pt 2): 888-890.
15. Batts KP, Moore SB, Perkins JD, Wiesner RH, Grambsch PM, Krom RA,. Influence of positive lymphocyte crossmatch and HLA mismatching on vanishing bile duct syndrome in human liver allografts. Transplantation 1988; 45: 376-379.
16. Ludwig J, Wiesner RH, Batts KP, Perkins JD, Krom RA,. The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation. Hepatology 1987; 7: 476-483.
17. Donaldson PT, Alexander GJ, O'Grady J, Neuberger J, Portmann B, Thick M, et al. Evidence for an immune response to HLA class I antigens in the vanishing-bileduct syndrome after liver transplantation. Lancet 1987; 1: 945-951.
18. O'Leary JG, Kaneku H, Susskind BM, Jennings LW, Neri MA, Davis GL, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am J Transplant 2011; 11: 1868-1876.
19. Kaneku H, O'Leary JG, Taniguchi M, Susskind BM, Terasaki PI, Klintmalm GB,. Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl 2012; 18: 984-992.
20. O'Leary JG, Klintmalm GB,. Impact of donor-specific antibodies on results of liver transplantation. Curr Opin Organ Transplant 2013; 18: 279-284.
21. O'Leary JG, Gebel HM, Ruiz R, Bray RA, Marr JD, Zhou XJ, et al. Class II alloantibody and mortality in simultaneous liver-kidney transplantation. Am J Transplant 2013; 13: 954-960.
22. Tait BD, Süsal C, Gebel HM, Nickerson PW, Zachary AA, Claas FH, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95: 19-47.
23. Demetris AJ, Murase N, Nakamura K, Iwaki Y, Yagihashi A, Valdivia L, et al. Immunopathology of antibodies as effectors of orthotopic liver allograft rejection. Semin Liver Dis 1992; 12: 51-59.
24. Knechtle SJ, Kolbeck PC, Tsuchimoto S, Coundouriotis A, Sanfilippo F, Bollinger RR,. Hepatic transplantation into sensitized recipients. Demonstration of hyperacute rejection. Transplantation 1987; 43: 8-12.
25. Knechtle SJ, Wolfe JA, Burchette J, Sanfilippo F, Bollinger RR,. Infiltrating cell phenotypes and patterns associated with hepatic allograft rejection or acceptance. Transplantation 1987; 43: 169-172.
26. Nakamura K, Murase N, Becich MJ, Furuya T, Todo S, Fung JJ, et al. Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model. Am J Pathol 1993; 142: 1383-1391.
27. Paterno F, Shiller M, Tillery G, O'Leary JG, Susskind B, Trotter J, Klintmalm GB,. Bortezomib for acute antibody-mediated rejection in liver transplantation. Am J Transplant 2012; 12: 2526-2531.
28. Takaya S, Bronsther O, Iwaki Y, Nakamura K, Abu-Elmagd K, Yagihashi A, et al. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation 1992; 53: 400-406.
29. Kobayashi M, Yagihashi A, Manez R, Takaya S, Noguchi K, Konno A, et al. Posttransplant donor-specific T-lymphocytotoxic antibody in liver transplant patients with a positive crossmatch. Transplant Proc 1992; 24: 2510-2511.
30. Mengel M, Sis B, Haas M, Colvin RB, Halloran PF, Racusen LC, et al.; for Banff Meeting Report Writing Committee. Banff 2011 meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012; 12: 563-570.
31. Taner T, Gandhi MJ, Sanderson SO, Poterucha CR, De Goey SR, Stegall MD, Heimbach JK,. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012; 12: 1504-1510.
32. Burns AM, Ma L, Li Y, Yin D, Shen J, Xu J, Chong AS,. Memory alloreactive B cells and alloantibodies prevent anti-CD154-mediated allograft acceptance. J Immunol 2009; 182: 1314-1324.
33. Bingaman AW, Farber DL,. Memory T cells in transplantation: generation, function, and potential role in rejection. Am J Transplant 2004; 4: 846-852.
34. Floyd TL, Koehn BH, Kitchens WH, Robertson JM, Cheeseman JA, Stempora L, et al. Limiting the amount and duration of antigen exposure during priming increases memory T cell requirement for costimulation during recall. J Immunol 2011; 186: 2033-2041.
35. Itescu S, Tung TC, Burke EM, Weinberg A, Moazami N, Artrip JH, et al. Preformed IgG antibodies against major histocompatibility complex class II antigens are major risk factors for high-grade cellular rejection in recipients of heart transplantation. Circulation 1998; 98: 786-793.
36. Itescu S, Tung TC, Burke EM, Weinberg AD, Mancini D, Michler RE, et al. An immunological algorithm to predict risk of high-grade rejection in cardiac transplant recipients. Lancet 1998; 352: 263-270.
37. Ballardini G, Mirakian R, Bianchi FB, Pisi E, Doniach D, Bottazzo GF,. Aberrant expression of HLA-DR antigens on bileduct epithelium in primary biliary cirrhosis: relevance to pathogenesis. Lancet 1984; 2: 1009-1013.
38. Demetris AJ, Lasky S, Van Thiel DH, Starzl TE, Whiteside T,. Induction of DR/IA antigens in human liver allografts. An immunocytochemical and clinicopathologic analysis of twenty failed grafts. Transplantation 1985; 40: 504-509.
39. Scornik JC, Soldevilla-Pico C, Van der Werf WJ, Hemming AW, Reed AI, Langham MR Jr, Howard RJ,. Susceptibility of liver allografts to high or low concentrations of preformed antibodies as measured by flow cytometry. Am J Transplant 2001; 1: 152-156.